Vaccine Therapy in Treating Patients With Malignant Melanoma
This trial is active, not recruiting.
|Treatment||polyvalent melanoma vaccine|
|Start date||July 2005|
|Trial identifier||NCT00128583, CDR0000439529, CV-MMAIT-5-001|
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with malignant melanoma.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Palm Springs, CA||Comprehensive Cancer Center at Desert Regional Medical Center||no longer recruiting|
|Santa Monica, CA||John Wayne Cancer Institute at Saint John's Health Center||no longer recruiting|
|Lakeland, FL||Lakeland Regional Cancer Center at Lakeland Regional Medical Center||no longer recruiting|
|Tampa, FL||H. Lee Moffitt Cancer Center and Research Institute at University of South Florida||no longer recruiting|
|Dayton, OH||CCOP - Dayton||no longer recruiting|
|Philadelphia, PA||Abramson Cancer Center of the University of Pennsylvania||no longer recruiting|
|Dallas, TX||Simmons Cancer Center at University of Texas Southwestern Medical Center at Dallas||no longer recruiting|
|Houston, TX||M.D. Anderson Cancer Center at University of Texas||no longer recruiting|
|Salt Lake City, UT||LDS Hospital||no longer recruiting|
|Sydney, Australia||Sydney Cancer Centre at Royal Prince Alfred Hospital||no longer recruiting|
|Brisbane, Australia||Princess Alexandra Hospital||no longer recruiting|
Male or female participants from 18 years up to 80 years old.
DISEASE CHARACTERISTICS: - Histologically confirmed malignant melanoma - At least 1 in-transit skin lesion measuring 3-10 mm in the longest diameter PATIENT CHARACTERISTICS: Age - 18 to 80 Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified
|Official title||Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™|
|Description||OBJECTIVES: - Determine the response in patients with in-transit cutaneous malignant melanoma treated with active immunotherapy comprising polyvalent melanoma vaccine (Canvaxin™). OUTLINE: This is an open-label, multicenter study. Patients receive polyvalent melanoma vaccine (Canvaxin™) subcutaneously to the armpit and groin areas every 2 weeks for approximately 10 weeks (5 doses) and then every 4 weeks for up to approximately 1 year of total treatment (total of 15 doses). Patients with no evidence of response at week 24 receive no further treatment. Patients whose disease continues to respond after completion of study treatment are eligible for a new study in which they will continue treatment with polyvalent melanoma vaccine (Canvaxin™). After completion of study treatment, patients are followed at 30 days. PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.|
Call for more information